Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | NPY4R | P50391 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328396 | 1.00 | NPY5R (0.41) | NPY5RNPY1RNPY4RACEOPRD1 | |
| SCHEMBL15328788 | 0.99 | ACE (0.42) | NPY5RNPY1RNPY4RACEOPRD1 | |
| SCHEMBL15328796 | 0.99 | ACE (0.42) | NPY5RNPY1RNPY4RACEOPRD1 | |
| SCHEMBL15328333 | 0.93 | OPRD1 (0.49) | NPY5RNPY1RNPY4RACEOPRD1 | |
| SCHEMBL15328329 | 0.93 | OPRD1 (0.49) | NPY5RNPY1RNPY4RACEOPRD1 | |
| SCHEMBL17206841 | 0.92 | OPRD1 (0.46) | NPY5RNPY1RNPY4ROPRD1OPRM1 | |
| SCHEMBL17082283 | 0.92 | OPRD1 (0.46) | NPY5RNPY1RNPY4ROPRD1OPRM1 | |
| SCHEMBL15344190 | 0.90 | OPRD1 (0.47) | OPRD1OPRM1OPRK1 | |
| SCHEMBL15344187 | 0.89 | OPRD1 (0.45) | OPRD1OPRM1OPRK1 | |
| SCHEMBL15328425 | 0.87 | HPGDS (0.42) | NPY5RNPY1RNPY4RACEOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | PTMS, VIP, MTPN | NPY5R 523/4885NPY1R 942/4885NPY4R 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.